It's been over a month since Forest Laboratories
The companies certainly wish the FDA would do something, but they're not sitting on their hands, waiting demurely. In true in-your-face fashion, Forest and Cypress released data from a third phase 3 trial, which confirmed the results of the two trials that the FDA is currently reviewing. Of course the companies were nice about it -- no need to piss off the FDA reviewers -- but I can only imagine that the executives were smiling as they issued the press release.
The companies didn't offer much data from the trial -- they're likely saving it for a scientific meeting. Hopefully the FDA won't need it, either; a request for the data could further delay the approval process, which is already nearly two months beyond the PDUFA date.
Forest and Cypress must be annoyed, but they've got company -- Eli Lilly's
I think we're likely to see an eventual approval. Hopefully this latest release of data reminds the FDA that it's got an application gathering dust. I'll join in the company's call: Approve the thing already.
- The Safest Investment You Can Make
- Experts Agree: You're Investing All Wrong
- The Stocks You'll Wish You'd Bought
Pfizer and Eli Lilly are Motley Fool Income Investor selections. Pfizer is also an Inside Value pick and the Fool owns shares of it. CV Therapeutics is a Rule Breakers recommendation. Try any of our Foolish newsletters today, free for 30 days.